Advances in the treatment of neuronal ceroid lipofuscinosis

Jonathan B. Rosenberg, Alvin Chen, Stephen M. Kaminsky, Ronald G. Crystal, Dolan Sondhi

Research output: Contribution to journalReview article

Abstract

Introduction: Neuronal ceroid lipofuscinoses (NCL) are neurodegenerative lysosomal storage disorders typically characterized by cognitive and visual impairments, epileptic seizures, ataxia, and deterioration of motor skills. Recent success of Brineura® for the treatment of neurologic manifestations of CLN2 disease has led to renewed interest in therapeutics for NCL. Despite complex challenges associated with CNS therapy, treatment modalities such as enzyme replacement therapy, gene therapy, stem cell therapy, and small molecule pharmacotherapy have been evaluated. Owing to the complexity of clinical endpoints which are often reliant on subjective clinical scales for the evaluation of candidate therapies, development of quantitative biomarkers for NCLs has become a necessity for the validation of potential treatments. Areas covered: For each NCL subtype, this review covers natural histories, animal models, biomarkers, therapeutic approaches, and preclinical and clinical research for therapeutic development. It corresponds to literature covering the years 1968-2019, with emphasis on the last decade. Expert opinion: Much progress has been made in NCL research, including better animal models, biomarkers and improved therapeutics with many of them reaching the clinical trial stage. In the future, successful therapies may involve the combination of two or more therapeutic modalities to provide therapeutic benefit especially as the patients grow older.

Original languageEnglish
Pages (from-to)473-500
Number of pages28
JournalExpert Opinion on Orphan Drugs
Volume7
Issue number11
DOIs
Publication statusPublished - 2 Nov 2019

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Therapeutics
Biomarkers
Animal Models
Enzyme Replacement Therapy
Motor Skills
Vision Disorders
Expert Testimony
Ataxia
Cell- and Tissue-Based Therapy
Neurologic Manifestations
Natural History
Research
Genetic Therapy
Epilepsy
Stem Cells

Keywords

  • adeno-associated virus (AAV)
  • ceroid lipofuscinosis
  • clinical trials
  • enzyme replacement therapy (ERT)
  • gene therapy
  • neuronal (CLN)
  • Neuronal ceroid lipofuscinoses (NCL)
  • palmitoyl protein thioesterase-1 (PPT1)
  • tripeptidyl peptidase-1 (TPP1)

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy
  • Pharmacology (medical)

Cite this

Advances in the treatment of neuronal ceroid lipofuscinosis. / Rosenberg, Jonathan B.; Chen, Alvin; Kaminsky, Stephen M.; Crystal, Ronald G.; Sondhi, Dolan.

In: Expert Opinion on Orphan Drugs, Vol. 7, No. 11, 02.11.2019, p. 473-500.

Research output: Contribution to journalReview article

Rosenberg, Jonathan B. ; Chen, Alvin ; Kaminsky, Stephen M. ; Crystal, Ronald G. ; Sondhi, Dolan. / Advances in the treatment of neuronal ceroid lipofuscinosis. In: Expert Opinion on Orphan Drugs. 2019 ; Vol. 7, No. 11. pp. 473-500.
@article{bcfda4d1553441a29a5050f6c3bac343,
title = "Advances in the treatment of neuronal ceroid lipofuscinosis",
abstract = "Introduction: Neuronal ceroid lipofuscinoses (NCL) are neurodegenerative lysosomal storage disorders typically characterized by cognitive and visual impairments, epileptic seizures, ataxia, and deterioration of motor skills. Recent success of Brineura{\circledR} for the treatment of neurologic manifestations of CLN2 disease has led to renewed interest in therapeutics for NCL. Despite complex challenges associated with CNS therapy, treatment modalities such as enzyme replacement therapy, gene therapy, stem cell therapy, and small molecule pharmacotherapy have been evaluated. Owing to the complexity of clinical endpoints which are often reliant on subjective clinical scales for the evaluation of candidate therapies, development of quantitative biomarkers for NCLs has become a necessity for the validation of potential treatments. Areas covered: For each NCL subtype, this review covers natural histories, animal models, biomarkers, therapeutic approaches, and preclinical and clinical research for therapeutic development. It corresponds to literature covering the years 1968-2019, with emphasis on the last decade. Expert opinion: Much progress has been made in NCL research, including better animal models, biomarkers and improved therapeutics with many of them reaching the clinical trial stage. In the future, successful therapies may involve the combination of two or more therapeutic modalities to provide therapeutic benefit especially as the patients grow older.",
keywords = "adeno-associated virus (AAV), ceroid lipofuscinosis, clinical trials, enzyme replacement therapy (ERT), gene therapy, neuronal (CLN), Neuronal ceroid lipofuscinoses (NCL), palmitoyl protein thioesterase-1 (PPT1), tripeptidyl peptidase-1 (TPP1)",
author = "Rosenberg, {Jonathan B.} and Alvin Chen and Kaminsky, {Stephen M.} and Crystal, {Ronald G.} and Dolan Sondhi",
year = "2019",
month = "11",
day = "2",
doi = "10.1080/21678707.2019.1684258",
language = "English",
volume = "7",
pages = "473--500",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Advances in the treatment of neuronal ceroid lipofuscinosis

AU - Rosenberg, Jonathan B.

AU - Chen, Alvin

AU - Kaminsky, Stephen M.

AU - Crystal, Ronald G.

AU - Sondhi, Dolan

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Introduction: Neuronal ceroid lipofuscinoses (NCL) are neurodegenerative lysosomal storage disorders typically characterized by cognitive and visual impairments, epileptic seizures, ataxia, and deterioration of motor skills. Recent success of Brineura® for the treatment of neurologic manifestations of CLN2 disease has led to renewed interest in therapeutics for NCL. Despite complex challenges associated with CNS therapy, treatment modalities such as enzyme replacement therapy, gene therapy, stem cell therapy, and small molecule pharmacotherapy have been evaluated. Owing to the complexity of clinical endpoints which are often reliant on subjective clinical scales for the evaluation of candidate therapies, development of quantitative biomarkers for NCLs has become a necessity for the validation of potential treatments. Areas covered: For each NCL subtype, this review covers natural histories, animal models, biomarkers, therapeutic approaches, and preclinical and clinical research for therapeutic development. It corresponds to literature covering the years 1968-2019, with emphasis on the last decade. Expert opinion: Much progress has been made in NCL research, including better animal models, biomarkers and improved therapeutics with many of them reaching the clinical trial stage. In the future, successful therapies may involve the combination of two or more therapeutic modalities to provide therapeutic benefit especially as the patients grow older.

AB - Introduction: Neuronal ceroid lipofuscinoses (NCL) are neurodegenerative lysosomal storage disorders typically characterized by cognitive and visual impairments, epileptic seizures, ataxia, and deterioration of motor skills. Recent success of Brineura® for the treatment of neurologic manifestations of CLN2 disease has led to renewed interest in therapeutics for NCL. Despite complex challenges associated with CNS therapy, treatment modalities such as enzyme replacement therapy, gene therapy, stem cell therapy, and small molecule pharmacotherapy have been evaluated. Owing to the complexity of clinical endpoints which are often reliant on subjective clinical scales for the evaluation of candidate therapies, development of quantitative biomarkers for NCLs has become a necessity for the validation of potential treatments. Areas covered: For each NCL subtype, this review covers natural histories, animal models, biomarkers, therapeutic approaches, and preclinical and clinical research for therapeutic development. It corresponds to literature covering the years 1968-2019, with emphasis on the last decade. Expert opinion: Much progress has been made in NCL research, including better animal models, biomarkers and improved therapeutics with many of them reaching the clinical trial stage. In the future, successful therapies may involve the combination of two or more therapeutic modalities to provide therapeutic benefit especially as the patients grow older.

KW - adeno-associated virus (AAV)

KW - ceroid lipofuscinosis

KW - clinical trials

KW - enzyme replacement therapy (ERT)

KW - gene therapy

KW - neuronal (CLN)

KW - Neuronal ceroid lipofuscinoses (NCL)

KW - palmitoyl protein thioesterase-1 (PPT1)

KW - tripeptidyl peptidase-1 (TPP1)

UR - http://www.scopus.com/inward/record.url?scp=85075680001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075680001&partnerID=8YFLogxK

U2 - 10.1080/21678707.2019.1684258

DO - 10.1080/21678707.2019.1684258

M3 - Review article

AN - SCOPUS:85075680001

VL - 7

SP - 473

EP - 500

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 11

ER -